Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis - PubMed (original) (raw)
Meta-Analysis
. 2011 Apr;106(4):644-59, quiz 660.
doi: 10.1038/ajg.2011.73. Epub 2011 Mar 15.
Affiliations
- PMID: 21407183
- DOI: 10.1038/ajg.2011.73
Meta-Analysis
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis
Alexander C Ford et al. Am J Gastroenterol. 2011 Apr.
Abstract
Objectives: Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory disorders of the gastrointestinal tract of unknown etiology. Evidence for treatment of the condition with biological therapies exists, but no systematic review and meta-analysis has examined this issue in its entirety.
Methods: MEDLINE, EMBASE, and the Cochrane central register of controlled trials were searched (through to December 2010). Trials recruiting adults with active or quiescent CD or UC and comparing biological therapies (anti-tumor necrosis factor-α (TNFα) antibodies or natalizumab) with placebo were eligible. Dichotomous symptom data were pooled to obtain relative risk (RR) of failure to achieve remission in active disease and RR of relapse of activity in quiescent disease once remission had occurred, with a 95% confidence interval (CI).
Results: The search strategy identified 3,061 citations, 27 of which were eligible. Anti-TNFα antibodies and natalizumab were both superior to placebo in inducing remission of luminal CD (RR of no remission=0.87; 95% CI 0.80-0.94 and RR=0.88; 95% CI 0.83-0.94, respectively). Anti-TNFα antibodies were also superior to placebo in preventing relapse of luminal CD (RR of relapse=0.71; 95% CI 0.65-0.76). Infliximab was superior to placebo in inducing remission of moderate to severely active UC (RR=0.72; 95% CI 0.57-0.91).
Conclusions: Biological therapies were superior to placebo in inducing remission of active CD and UC, and in preventing relapse of quiescent CD.
Comment in
- When meta-analysis misleads.
Yang M, Robinson AM, Pollack PF. Yang M, et al. Am J Gastroenterol. 2011 Nov;106(11):2043; author reply 2044. doi: 10.1038/ajg.2011.245. Am J Gastroenterol. 2011. PMID: 22056581 No abstract available. - Biologics in fistulizing Crohn's disease: so near, yet so far.
Atreja A, Bahuva R, Sands BE. Atreja A, et al. Am J Gastroenterol. 2011 Nov;106(11):2045-6; author reply 2046. doi: 10.1038/ajg.2011.273. Am J Gastroenterol. 2011. PMID: 22056584 No abstract available. - Efficacy of certolizumab pegol in Crohn's disease: response to ford et Al.
Kayhan C, Pierre-Louis B, Sen D, Serna M. Kayhan C, et al. Am J Gastroenterol. 2012 Feb;107(2):321; author reply 321-2. doi: 10.1038/ajg.2011.381. Am J Gastroenterol. 2012. PMID: 22306947 No abstract available.
Similar articles
- Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis.
Ford AC, Bernstein CN, Khan KJ, Abreu MT, Marshall JK, Talley NJ, Moayyedi P. Ford AC, et al. Am J Gastroenterol. 2011 Apr;106(4):590-9; quiz 600. doi: 10.1038/ajg.2011.70. Epub 2011 Mar 15. Am J Gastroenterol. 2011. PMID: 21407179 - Natalizumab for induction of remission in Crohn's disease.
Macdonald JK, McDonald JW. Macdonald JK, et al. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD006097. doi: 10.1002/14651858.CD006097. Cochrane Database Syst Rev. 2006. PMID: 16856112 Updated. - Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis.
Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, Talley NJ, Moayyedi P. Khan KJ, et al. Am J Gastroenterol. 2011 Apr;106(4):661-73. doi: 10.1038/ajg.2011.72. Epub 2011 Mar 15. Am J Gastroenterol. 2011. PMID: 21407187 - Natalizumab for induction of remission in Crohn's disease.
MacDonald JK, McDonald JW. MacDonald JK, et al. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD006097. doi: 10.1002/14651858.CD006097.pub2. Cochrane Database Syst Rev. 2007. PMID: 17253580 Updated. - Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C, Hughes C, Naldi L, Afach S, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. PMID: 33871055 Free PMC article. Updated.
Cited by
- New Onset, Aggravation and Recurrence of Crohn's Disease upon Treatment with Three Different Tumor Necrosis Factor Inhibitors.
Zeitz J, Enderlin S, Biedermann L, Turina M, Leibl S, Prakash M, Rogler G, Misselwitz B. Zeitz J, et al. Case Rep Gastroenterol. 2015 Apr 24;9(1):106-12. doi: 10.1159/000381637. eCollection 2015 Jan-Apr. Case Rep Gastroenterol. 2015. PMID: 26034472 Free PMC article. - Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease.
Di Sabatino A, Liberato L, Marchetti M, Biancheri P, Corazza GR. Di Sabatino A, et al. Intern Emerg Med. 2011 Oct;6 Suppl 1:17-27. doi: 10.1007/s11739-011-0673-9. Intern Emerg Med. 2011. PMID: 22009609 Review. - Inflammatory bowel disease: towards a personalized medicine.
Flamant M, Roblin X. Flamant M, et al. Therap Adv Gastroenterol. 2018 Jan 10;11:1756283X17745029. doi: 10.1177/1756283X17745029. eCollection 2018. Therap Adv Gastroenterol. 2018. PMID: 29383027 Free PMC article. Review. - Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis.
Lv R, Qiao W, Wu Z, Wang Y, Dai S, Liu Q, Zheng X. Lv R, et al. PLoS One. 2014 Jan 27;9(1):e86692. doi: 10.1371/journal.pone.0086692. eCollection 2014. PLoS One. 2014. PMID: 24475168 Free PMC article. - Evidence-based clinical practice guidelines for inflammatory bowel disease.
Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Matsuoka K, et al. J Gastroenterol. 2018 Mar;53(3):305-353. doi: 10.1007/s00535-018-1439-1. Epub 2018 Feb 10. J Gastroenterol. 2018. PMID: 29429045 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical